SARS-CoV-2 infection in severe asthma is associated with worsening of COVID-19 through respiratory NLRP3 inflammasome activation
- PMID: 35871401
- PMCID: PMC9349818
- DOI: 10.1111/all.15452
SARS-CoV-2 infection in severe asthma is associated with worsening of COVID-19 through respiratory NLRP3 inflammasome activation
Comment on
-
Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19.Allergy. 2022 Jan;77(1):173-185. doi: 10.1111/all.14972. Epub 2021 Jun 19. Allergy. 2022. PMID: 34080210 Free PMC article.
References
REFERENCES
-
- Eggert LE, He Z, Collins W, et al. Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19. Allergy. 2022;77(1):173-185.
-
- Bloom CI, Cullinan P, Wedzicha JA. Asthma phenotypes and COVID-19 risk: a population-based observational study. Am J Respir Crit Care Med. 2022;205(1):36-45.
-
- Zheng J, Wong LR, Li K, et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature. 2021;589(7843):603-607.
-
- Jeong JS, Lee KB, Kim SR, et al. Airway epithelial phosphoinositide 3-kinase-δ contributes to the modulation of fungi-induced innate immune response. Thorax. 2018;73(8):758-768.
-
- Vora SM, Lieberman J, Wu H. Inflammasome activation at the crux of severe COVID-19. Nat Rev Immunol. 2021;21(11):694-703.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
